The Link Between Physical Activity and Brain Health in Healthy Adults
NCT07025070, Recruiting, Technical University of Madrid
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Link Between Physical Activity and Brain Health in Healthy Adults | ClinicalTrials.gov |
| NCT number | NCT07025070 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Technical University of Madrid | ClinicalTrials.gov |
| Conditions | Alzheimer Disease, Inactivity, Preventive Therapy | ClinicalTrials.gov |
| First posted | 2025-06-17 | ClinicalTrials.gov |
| Last updated | 2025-06-17 | ClinicalTrials.gov |
Registered outcomes 32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Concentration of brain-derived neurotrophic factor (BDNF) in plasma (pg/mL) | Baseline | Measured with ELISA kit (e.g., R\&D Systems, Cat. #DY248). Higher BDNF reflects greater neurotrophic support. | ClinicalTrials.gov |
| Primary | Concentration of total tau protein in plasma (pg/mL) | Baseline | Assayed by high-sensitivity ELISA (e.g., Cusabio, Cat. #CSB-E13913h). Greater tau concentration indicates increased axonal injury or neurodegeneration. | ClinicalTrials.gov |
| Primary | Hippocampal volume measured by high-resolution 3 T T1-weighted MRI (mm³) | Baseline | Volume extracted with FreeSurfer; Larger values indicate greater hippocampal integrity | ClinicalTrials.gov |
| Primary | Resting-state functional connectivity between primary motor cortex and supplementary motor area measured by 3 T fMRI (Fisher-Z) | Baseline | Fisher-Z transformed correlation computed with CONN; Higher values indicate stronger connectivity | ClinicalTrials.gov |
| Primary | Digit Span Forward maximum span length (digits) | Baseline | Attention assessed with Wechsler Adult Intelligence Scale-IV Digit Span Forward subtest; Maximum correctly repeated digit sequence recorded. Higher scores indicate better attention/short-term memory capacity. | ClinicalTrials.gov |
| Primary | Trail Making Test Part A completion time (seconds) | Baseline | Visual attention and processing speed measured by TMT-A; time to connect 25 numbers in ascending order recorded. Shorter times indicate better performance. | ClinicalTrials.gov |
| Primary | Digit Span Backward maximum span length (digits) | Baseline | Working memory measured with WAIS-IV Digit Span Backward; Longest correctly repeated backward sequence recorded. Higher scores indicate better working memory. | ClinicalTrials.gov |
| Primary | Trail Making Test Part B completion time (seconds) | Baseline | Executive function (set-shifting) assessed by TMT-B; Time to alternately connect numbers and letters recorded. Shorter times indicate better executive control. | ClinicalTrials.gov |
| Primary | Verbal fluency (F-A-S) total words in 60 s (count) | Baseline | Phonemic fluency tested with Controlled Oral Word Association Test (letters F, A, S, 60 s each); total correct words across three letters. Higher counts indicate better executive retrieval fluency. | ClinicalTrials.gov |
| Primary | Stroop Color-Word interference score (seconds) | Baseline | Inhibition assessed with Golden Stroop test; The count of completions within 45 seconds is recorded. Lower times reflect better inhibitory control. | ClinicalTrials.gov |
| Primary | Montreal Cognitive Assessment (MoCA) total score (0 - 30 points) | Baseline | 10-minute screening of global cognition covering memory, attention, language, visuospatial, and executive domains. Values ≥ 26 are considered normal. Higher scores indicate better cognition. | ClinicalTrials.gov |
| Primary | Number of participants carrying at least one APOE ε4 allele (count of participants) | Baseline | Genomic DNA isolated from EDTA whole blood; APOE genotyping by TaqMan SNP assays rs429358 and rs7412. Any ε4-containing genotype (ε2/ε4, ε3/ε4, ε4/ε4) classified as "ε4 carrier". Higher counts = higher ε4 prevalence. | ClinicalTrials.gov |
| Secondary | Maximal oxygen uptake (VO₂max) measured by CPET with ramp protocol on treadmill (mL·kg-¹·min-¹) | Baseline | Cardiopulmonary exercise test performed on treadmill using Ramp incremental ramp. Breath-by-breath gas exchange collected via metabolic cart. VO₂max defined as the highest 30-s average during the test; Higher values indicate better cardiorespiratory fitness. | ClinicalTrials.gov |
| Secondary | Mean daily minutes of moderate-to-vigorous physical activity measured by ActiGraph wGT3X-BT accelerometer over 7 days (min/day) | Baseline | Device worn on non-dominant wrist 24 h/day for 7 consecutive days. Raw data (100 Hz) processed in ActiLife with 10 s epochs; Freedson adult cut-points ≥ 1 952 counts·min-¹ define MVPA. Higher values indicate greater physical activity. | ClinicalTrials.gov |
| Secondary | Body mass index (BMI) calculated from weight and stadiometer-measured height (kg/m²) | Baseline | Height measured to 0.1 cm with height measuring rod. Weight obtained from InBody system. BMI = weight ÷ height². Higher BMI indicates greater overall adiposity. | ClinicalTrials.gov |
| Secondary | Peak force of mid-thigh-pull test measured by portable force dynamometer (N) | Baseline | Participants perform two maximal isometric mid-thigh pulls on calibrated dynamometer with 60 s rest. The higher of two trials recorded as peak force. Greater values indicate stronger lower-limb strength. | ClinicalTrials.gov |
| Secondary | Handgrip strength measured by grip dynamometer (kg) | Baseline | Standing posture, shoulder neutral, elbow extended. Two maximal squeezes per hand with dynamometer; 30 s rest between trials. Best value used for analysis. Higher values reflect greater grip strength. | ClinicalTrials.gov |
| Secondary | Timed Up-and-Go (TUG) test completion time (seconds) | Baseline | Participants stand up from a 45-cm chair, walk 3 m, turn, return, and sit; time recorded by timers. Two trials with 1 min rest; Shorter time retained. Lower times represent better agility. | ClinicalTrials.gov |
| Secondary | Balance stability and speed score measured by TANITA force platform (unitless) | Baseline | Balance and speed assessed on TANITA analyzer in eyes-open seated posture; Stand-up as fast as possible when signaled, repeat 3 times to get an optimal value; Manufacturer's composite stability index automatically computed (range 0-100). One 30-s trial; higher scores denote better balance. | ClinicalTrials.gov |
| Secondary | Percentage body fat measured by multifrequency bioimpedance analyzer InBody system (%) | Baseline | Participants barefoot, InBody 770 provides whole-body fat percentage derived from segmental impedance; Higher values denote greater adiposity. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)